- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05514340
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase-II Trial to Assess Safety, and Efficacy of Sovateltide in the Treatment of Hypoxic-ischemic Encephalopathy in Neonates
Study Overview
Status
Intervention / Treatment
Detailed Description
Neonatal encephalopathy due to perinatal asphyxia is known as hypoxic-ischemic encephalopathy (HIE). HIE is a serious neurological complication affecting premature and full-term neonates, resulting from oxygen deprivation and reduced blood flow to the neonatal brain, leading to neuronal and white matter injury. Currently, no well-established therapies are considered effective for neonatal HIE. The standard of care at present includes supportive management to maintain cerebral perfusion, metabolic balance, and seizure detection and treatment. Currently, the only neuroprotective treatment for HIE is therapeutic hypothermia. However, improvement in patient outcomes following therapy has been moderate, with only 1 in 6 infants benefitting from therapeutic hypothermia.
Additionally, therapeutic hypothermia is time-sensitive, having a narrow therapeutic window wherein therapy must be initiated within 6 hours of delivery to be effective. Timely initiation is also restricted to those neonatal units having adequate equipment and trained staff for therapeutic hypothermia. Death or disability is reported to occur in 55% of infants receiving therapeutic hypothermia. To the best of our knowledge, there is no pharmacotherapy available for the treatment of HIE. Hence, there is a significant unmet medical need.
ETB receptors located widely throughout the CNS are a necessary component of the developing nervous system and also promote neurorestorative processes involving neurogenesis and synaptogenesis. There was an increased expression of neural progenitor markers, NeuroD1 and Double Cortin, and neural markers for mature neurons, NeuN was observed in the sovateltide group compared to vehicle. In addition, Sovateltide increased the expression of presynaptic markers (synapsin1 and synaptophysin) and post-synaptic marker (Postsynaptic Density-95) compared to vehicle. Our results suggest that sovateltide treatment helps recruit and differentiate neural progenitor cells and augments synaptogenesis and endogenous neurorestorative processes.
Sovateltide is a synthetic analog of ET-1 synthesized in 1992 and is a highly specific ETB receptor agonist. We and others have conducted studies to determine the effects of sovateltide upon its interaction with neural ETB receptors and have found that it enhances angiogenesis and neurogenesis and promotes repair and regeneration. This is indicated by neuronal cell proliferation, alleviation of oxidative stress, improvement of neurological and motor functions, and increase in anti-apoptotic markers. In our preclinical study, sovateltide was shown to have neuroprotective effects by promoting repair and regeneration in the brain in a neonatal rat model of HIE. The study showed that sovateltide treatment alone or in combination with hypothermia significantly (p<0.01) increased ETB receptor expression compared to vehicle-treated rat pups. In addition, enhanced VEGF and NGF expression were observed in rat pups treated with Sovateltide alone or in combination with hypothermia compared to vehicle-treated rat pups (p<0.0001, p<0.0001). Sovateltide alone and in combination with hypothermia also demonstrated a significantly reduced number of apoptotic cells compared to the control group. Furthermore, oxidative stress markers, including malondialdehyde, reduced glutathione, and superoxide dismutase was, significantly improved (p<0.0001, p<0.0001, p<0.0001) in those rat pups treated with sovateltide.
Sovateltide was safe and well-tolerated in a Phase I trial (CTRI/2016/11/007509) in healthy human volunteers. In addition, we conducted human studies in patients with cerebral ischemic stroke (NCT04046484, CTRI/2017/11/010654; NCT04047563, CTRI/2019/09/021373), Alzheimer's disease (NCT04052737, CTRI/2017/12/016394), and acute spinal cord injury (NCT04054414, CTRI/2018/12/016667) patients. In summary, about 300 patients have been treated with sovateltide, and no drug-related adverse event has been reported to date.
We plan to conduct a phase II clinical study to evaluate the safety and efficacy of sovateltide therapy along with supportive management in neonates with perinatal asphyxia (HIE). The dose of sovateltide proposed for this phase II study is 0.3µg/kg same as used in the phase II study in ischemic stroke.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Manish S Lavhale
- Phone Number: +91 9873847397
- Email: manish.lavhale@pharmazz.com
Study Locations
-
-
Karnataka
-
Mangalore, Karnataka, India, 575002
- Recruiting
- Father Muller Medical College Hospital
-
Contact:
- Pavan Hedge
- Email: pavanhegde@hotmail.co
-
-
Punjab
-
Ludhiana, Punjab, India, 141008
- Recruiting
- Christian Medical College and Hospital
-
Contact:
- Gurmeet Kaur
- Email: navgur@gmail.com
-
-
Telangana
-
Hyderabad, Telangana, India, 500 004
- Not yet recruiting
- Niloufer Hospital
-
Contact:
- Swapna Lingaldinna
-
-
Uttar Pradesh
-
Kanpur, Uttar Pradesh, India, 208002
- Not yet recruiting
- GSVM Medical College
-
Contact:
- Yashwant K Rao
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Either sex with ≥ 36 weeks of gestational age
- Receiving supportive management for perinatal asphyxia
Perinatal depression, based on at least one of the following:
- Apgar score of <5 at 10 minutes
- Need for resuscitation (chest compressions or mechanical ventilation) at birth
- pH <7.00 or base deficit ≥ 16 mmol/liter in the cord or arterial blood within 60 minutes of birth
- Moderate/severe encephalopathy evident by at least 3 of 6 modified Sarnat criteria, present between 1 to 6 hours of birth.
- Informed consent by one of the parents or a legal representative
Exclusion Criteria:
- Gestational age <36 weeks
- Admitted to hospital 12-hours after birth
- A genetic or congenital condition that affects neuronal development
- TORCH infection
- Neonatal sepsis
- Complex congenital heart disease
- Severe dysmorphic feature
- Microcephaly (head circumference < 2 Standard Deviations below mean for gestational age)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Normal Saline + Standard of care
Patients will receive the best available standard of care.
Normal saline will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
|
Sovateltide is an endothelin-B receptor agonist.
It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients.
In this arm normal saline along with standard treatment will be given for active comparison.
Other Names:
|
Experimental: Sovateltide + Standard of care
Patients will receive the best available standard of care.
Dose of sovateltide (0.3 µg/kg) will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
|
Sovateltide is an endothelin-B receptor agonist.
It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients.
In this arm sovateltide along with standard treatment will be given for active comparison.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with death or disability (moderate/severe)
Time Frame: 24 months
|
Percentage of patients with death or disability (moderate/severe).
Severe disability is defined as any of the following: a Bayley composite cognitive score <70, a GMFCS grade of level 3 to 5, hearing impairment requiring hearing aids, or blindness (vision <20/200).
Moderate disability is defined as a composite cognitive score 70 - 84, in addition, one or more of the following: GMFCS grade of level 2, unilateral blindness (vision 20/200 in only one eye), or hearing impairment with no amplification/cochlear implant.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bayley Scales of Infant and Toddler Development Scores
Time Frame: 24 months
|
Changes in Bayley Scales of Infant and Toddler Development Scores.
Cognitive, Language, Motor, Social-Emotional, and General Adaptive Scales Score as assessed by Bayley Scales of Infant and Toddler Development (BSID)TM measured at 6 months after initiation of treatment and then at every 6 months interval.
|
24 months
|
Disabling cerebral palsy
Time Frame: 24 months
|
Change in the proportion of children with disabling cerebral palsy
|
24 months
|
Seizures
Time Frame: 24 months
|
Change in the proportion of patients with seizures.
Clinical or electrical seizures at birth, at 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 7 days, 30 days, 6 months after initiation of treatment, and then at every 6 months interval.
|
24 months
|
Brain injury
Time Frame: 14 days]
|
The number of patients with brain injury (MRI or EEG evidence of brain injury).
Abnormal MRI findings based on NICHD neonatal network score within 1 to 2 weeks of initiation of treatment.
|
14 days]
|
Blindness or hearing impairment
Time Frame: 24 months
|
Change in the proportion of patients with blindness or hearing impairment
|
24 months
|
Adverse events
Time Frame: 24 months
|
Incidence of sovateltide-related adverse events
|
24 months
|
Tolerance
Time Frame: 7 days
|
The number of patients not receiving complete treatment due to intolerance to sovateltide.
|
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Anil Gulati, Chairman and CEO
Publications and helpful links
General Publications
- Ranjan AK, Briyal S, Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke. Sci Rep. 2020 Jul 29;10(1):12737. doi: 10.1038/s41598-020-69673-w.
- Ramos MD, Briyal S, Prazad P, Gulati A. Neuroprotective Effect of Sovateltide (IRL 1620, PMZ 1620) in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy. Neuroscience. 2022 Jan 1;480:194-202. doi: 10.1016/j.neuroscience.2021.11.027. Epub 2021 Nov 23.
- Ranjan AK, Gulati A. Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders. Int J Mol Sci. 2022 Mar 15;23(6):3146. doi: 10.3390/ijms23063146.
- Gulati A, Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke. CNS Drugs. 2021 Jan;35(1):85-104. doi: 10.1007/s40263-020-00783-9. Epub 2021 Jan 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Infant, Newborn, Diseases
- Signs and Symptoms, Respiratory
- Death
- Hypoxia, Brain
- Brain Ischemia
- Ischemia
- Brain Diseases
- Hypoxia
- Hypoxia-Ischemia, Brain
- Asphyxia
- Asphyxia Neonatorum
Other Study ID Numbers
- PMZ-1620/CT-2.4/2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoxic-Ischemic Encephalopathy
-
Johns Hopkins UniversityUniversity of MarylandCompletedEncephalopathy, Hypoxic-IschemicUnited States
-
Sajjad RahmanUnknownSevere Hypoxic Ischemic Encephalopathy | Moderate Hypoxic Ischemic EncephalopathyTurkey, Egypt, Malaysia, Qatar, Saudi Arabia, United Arab Emirates
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHypoxia, Brain | Hypoxia-Ischemia, Brain | Hypoxic-Ischemic Encephalopathy | Infant, Newborn | Ischemic-Hypoxic Encephalopathy | Encephalopathy, Hypoxic-IschemicUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEncephalopathy, Hypoxic IschemicItaly
-
Cliniques universitaires Saint-Luc- Université...Active, not recruitingEncephalopathy, Hypoxic-IschemicBelgium
-
University Hospital, GrenobleUnknownIschemic-Hypoxic EncephalopathyFrance
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedHypoxia, Brain | Hypoxia-Ischemia, Brain | Hypoxic-Ischemic Encephalopathy | Infant, Newborn | Ischemic-Hypoxic Encephalopathy | Encephalopathy, Hypoxic-IschemicUnited States
-
Navy General Hospital, BeijingDaping Hospital and the Research Institute of Surgery of the Third Military... and other collaboratorsUnknownHypoxic-Ischemic EncephalopathyChina
-
Istanbul Training and Research HospitalCompletedHypoxic-Ischemic EncephalopathyTurkey
-
University of FloridaAmerican Heart AssociationCompleted
Clinical Trials on Normal Saline along with standard treatment
-
Pharmazz, Inc.Completed
-
Pharmazz, Inc.Recruiting
-
Pharmazz, Inc.CompletedCerebral Infarction | Stroke, Acute | Cerebral IschemiaIndia
-
Pharmazz, Inc.Completed
-
Pharmazz, Inc.CompletedHypovolemic ShockIndia
-
Riphah International UniversityCompletedMills Manipulation and Mulligan PRP Affect Pain, Grip Strength and Function on Lateral EpicondylitisLateral EpicondylitisPakistan
-
Riphah International UniversityRecruiting
-
Riphah International UniversityCompleted
-
The Hospital for Sick ChildrenCompleted
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly